NEW YORK, NY / ACCESSWIRE / October 31, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Fortrea Holdings Inc. ("Fortrea" or the "Company") (NASDAQ:FTRE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, NY / ACCESSWIRE / October 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fortrea Holdings Inc. ("Fortrea Holdings Inc.") (NASDAQ:FTRE) concerning possible violations of federal securities laws. Jefferies downgraded Fortrea on September 25, 2024, citing perceived weaknesses in the Company's business model as a contract research organization amid pressure on biotechnology funding.
NEW YORK, NY / ACCESSWIRE / October 29, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Fortrea Holdings Inc. ("Fortrea" or the "Company") (NASDAQ:FTRE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, NY / ACCESSWIRE / October 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fortrea Holdings Inc. ("Fortrea Holdings Inc.") (NASDAQ:FTRE) concerning possible violations of federal securities laws. Jefferies downgraded Fortrea on September 25, 2024, citing perceived weaknesses in the Company's business model as a contract research organization amid pressure on biotechnology funding.
NEW YORK, NY / ACCESSWIRE / October 27, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Fortrea Holdings Inc. ("Fortrea" or the "Company") (NASDAQ:FTRE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, NY / ACCESSWIRE / October 23, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Fortrea Holdings Inc. ("Fortrea" or the "Company") (NASDAQ:FTRE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, NY / ACCESSWIRE / October 23, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fortrea Holdings Inc. ("Fortrea Holdings Inc.") (NASDAQ:FTRE) concerning possible violations of federal securities laws. Jefferies downgraded Fortrea on September 25, 2024, citing perceived weaknesses in the Company's business model as a contract research organization amid pressure on biotechnology funding.
NEW YORK, NY / ACCESSWIRE / October 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fortrea Holdings Inc. ("Fortrea Holdings Inc.") (NASDAQ:FTRE) concerning possible violations of federal securities laws. Jefferies downgraded Fortrea on September 25, 2024, citing perceived weaknesses in the Company's business model as a contract research organization amid pressure on biotechnology funding.
NEW YORK, NY / ACCESSWIRE / October 19, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Fortrea Holdings Inc. ("Fortrea" or the "Company") (NASDAQ:FTRE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, NY / ACCESSWIRE / October 15, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fortrea Holdings Inc. ("Fortrea Holdings Inc.") (NASDAQ:FTRE) concerning possible violations of federal securities laws. Jefferies downgraded Fortrea on September 25, 2024, citing perceived weaknesses in the Company's business model as a contract research organization amid pressure on biotechnology funding.
NEW YORK, NY / ACCESSWIRE / October 15, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Fortrea Holdings Inc. ("Fortrea" or the "Company") (NASDAQ:FTRE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, NY / ACCESSWIRE / October 15, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fortrea Holdings Inc. ("Fortrea Holdings Inc.") (NASDAQ:FTRE) concerning possible violations of federal securities laws. Jefferies downgraded Fortrea on September 25, 2024, citing perceived weaknesses in the Company's business model as a contract research organization amid pressure on biotechnology funding.